ライフサイエンスコーパス: skin test

1 QuantiFERON-TB Gold In-Tube, and tuberculin skin test.

2 diate hypersensitivity diagnosed by positive skin test.

3 ciated with positivity of QFT and tuberculin skin tests.

4 d in vitro biomarkers and the uselessness of skin tests.

5 base of migrants with predominately positive skin tests.

6 should be considered as a complement to late skin tests.

7 ensitization has not been proven by positive skin tests.

8 should be performed in case of negativity on skin tests.

9 ostic workup may be considered, particularly skin tests.

10 ockroach allergen extracts used for clinical skin tests.

11 Allergens were used in IgE ELISA and skin testing.

12 cal and radiological findings and tuberculin skin testing.

13 raphy, molecular diagnostics, and tuberculin skin testing.

14 aximize the potential benefits of penicillin skin testing.

15 f pharmacists in the provision of penicillin skin testing.

16 Hypersensitivity reaction rate after allergy skin testing (17%; 95% CI: 7%, 29%; zero of 21 studies)

17 ulate after intradermal challenge with a VZV skin test Ag.

18 he group.We recommend drug concentration for skin testing aiming to achieve a specificity of at least

19 ish (raw and heated) as well as for standard skin test allergens (prepared by Torii pharmaceuticals)

20 A positive tuberculin skin test alone among clinical laboratory findings was s

21 m/cilastatin and meropenem; 130 of them were skin-tested also with ertapenem.

22 tive volunteers, 32% had a positive rAed a 3 skin test and 46% had specific IgE.

23 story of tuberculosis then used a tuberculin skin test and an interferon-gamma release assay (QuantiF

24 drug dose, latency periods, test results of skin test and cellular assays, and tolerated drugs in su

25 -based study assessing use of the tuberculin skin test and IFN-gamma release assays among children (n

26 At 6 months, the patient's skin test and IgE to peanuts were negative.

27 ted tuberculosis independently of tuberculin skin test and index-case drug sensitivity results.

28 s in young children and trends in tuberculin skin test and interferon gamma-release assays.

29 infection is identified using the tuberculin skin test and interferon-gamma (IFN-gamma) release assay

30 nd high aerosols had differential tuberculin skin test and interferon-gamma release assay responses.

31 s were categorised into distinct phenotypes: skin test and lesion positive vs skin test negative on m

32 The practicability and validity of skin test and other diagnostic procedures need further a

33 ted; all participants underwent a tuberculin skin test and QuantiFERON-TB Gold assay.

34 ldren with no documented contact, tuberculin skin test and QuantiFERON-TB Gold In-Tube positivity was

35 Overall agreement between the tuberculin skin test and the QFT test was moderate (81.06%; kappa c

36 Rates of positivity for the tuberculin skin test and the QFT test were low in study participant

37 Immune-based TB screening (tuberculin skin test and/or interferon-gamma release assay) was per

38 Immune-based TB screening (tuberculin skin test and/or interferon-gamma release assay) was per

39 Skin testing and basophil activation tests were performe

40 ensitivity (which include drug provocations, skin testing and in vitro testing) and provides, when da

41 e value and limitations of clinical history, skin testing and laboratory investigations for both peni

42 ues, such as the animal-level sensitivity of skin testing and slaughter inspection, to observed bTB e

43 ed in clinical studies and extracts used for skin testing and to identify trace levels of allergens i

44 tes skin mast cells and is therefore used in skin tests and as an inducer of experimental itch.

45 n SOT candidates/recipients using tuberculin skin tests and interferon-gamma release assays and risk

46 Skin tests and measurement of serum levels of immunoglob

47 etermined by combining symptom patterns with skin tests and measurement of serum specific IgE levels.

48 The efficacy of skin tests and poor use of laboratory tests are underlin

49 es, a skin biopsy was obtained from positive skin tests and positive DPT.

50 Skin tests and serum-specific IgE assays were repeated 1

51 ological activity and is suitable for use in skin tests and specific IgE assays in mosquito-allergic

52 Skin tests and specific IgE quantification appear to hav

53 We sought to assess the accuracy of skin tests and specific IgE quantification in the diagno

54 s reporting a penicillin allergy and in whom skin tests and/or specific IgE quantification were perfo

55 We performed clinical assessment, tuberculin skin test, and chest radiography in all eligible childre

56 Egg white-specific IgE, skin testing, and basophil activation decreased similarl

57 is infection was measured through tuberculin skin testing, and relative risks were calculated using m

58 sults of specific IgE (sIgE) determinations, skin tests, and basophil activation tests were correlate

59 inical and epidemiological studies with past skin test antigens, the composition of past and current

60 Giant reactions to the tuberculin skin test are extremely rare and have been previously re

61 Skin tests are of paramount importance for the evaluatio

62 Drug skin tests are often not carried out because of lack of

63 ce of allergy diagnosis was shown to rely on skin tests as first option in almost 2/3 of all types of

64 possible causes of CSU, and autologous serum skin test (ASST) response.

65 (UAS7 and quality of life); autologous serum skin test (ASST); IgG anti-FcepsilonRI and IgG anti-IgE;

66 U including the response to autologous serum skin testing (ASST).

67 ay have clinical implications for the use of skin test-based diagnosis of microbial infections.

68 Data from history, symptoms, skin tests, basophil activation tests, and oral challeng

69 reatment, however, we recommend pretreatment skin tests because negative responses indicate tolerabil

70 beta-lactam allergy skin testing (BLAST) is recommended by antimicrobial ste

71 -lactams, however, we recommend pretreatment skin tests, both because rare cases of cross-reactivity

72 erculosis in China might be overestimated by skin tests compared with interferon-gamma release assays

73 dies designed to establish and validate drug skin test concentration using standard protocols.

74 This survey revealed that skin tests continue to be the main diagnostic procedure

75 The tuberculin skin test conversion rates (>6 mm) of the two chambers w

76 agnostics currently rely on patient history, skin tests, determination of serum specific IgE antibodi

77 Allergy has performed a literature search on skin test drug concentration in MEDLINE and EMBASE, revi

78 Of 278 ST patients, 179 (64%) were skin test eligible; 43 (24%) received testing and none w

79 In vitro tests can complement skin tests, especially in patients with negative or equi

80 detailed history, cautious interpretation of skin tests, foetal Rh genotyping from maternal blood and

81 t-allergic children underwent double-blinded skin testing, followed by parent-led peanut introduction

82 ffer advantages compared with the tuberculin skin test for identifying TB infection, and improve targ

83 icing physicians will be unfamiliar with how skin testing for coccidioidomycosis might be useful in p

84 based on the severity of the initial HSR and skin testing for guiding taxane reintroduction in patien

85 According to current guidelines, skin testing for hymenoptera venom allergy should be per

86 Skin testing for vancomycin sensitivity showed negative

87 from immunoglobulin E serology analysis and skin tests for common food antigens.

88 preference to T-SPOT.TB (and the tuberculin skin test) for diagnosing tuberculous uveitis.

89 with anti-phenolic glycolipid I serology and skin tests from the same individual, from 113 leprosy pa

90 LTBI was ascertained from tuberculin skin tests given during the 1999-2000 National Health an

91 -naive HIV-infected patients with tuberculin skin test >/=5 mm were recruited from Khayelitsha day ho

92 Skin testing-guided elimination diet has proved unsucces

93 Skin tests had a summary sensitivity of 30.7% (95% CI, 1

94 one case with grade 1 reaction and negative skin tests had an anaphylactic shock to the OC.

95 Their role in allergy skin testing has never been evaluated.

96 Allergic skin tests have to be performed 4-6 weeks after an aller

97 ergy evaluation with history-appropriate PCN skin testing: if skin test negative, give cefazolin (ST-

98 Based on prospective data (questionnaires, skin tests, IgE), children were assigned to wheeze pheno

99 a, IGRAs have advantages over the tuberculin skin test in specific patient populations and in certain

100 rculous infection, measured using tuberculin skin testing in a cohort of schoolchildren, a median of

101 Skin testing in duplicate, correlation between case hist

102 We aimed to assess the role of skin testing in the diagnosis of PPI-related immediate h

103 sis of drug hypersensitivity was obtained by skin tests in 72.9%, laboratory tests only in 2.4% of ca

104 Data are limited about the value of skin tests in the diagnosis of proton pump inhibitor (PP

105 s and 39% had access to inpatient penicillin skin testing, indicating that the majority of US hospita

106 rth, human immunodeficiency virus infection, skin test induration >=10 mm, shared bedroom with an ind

107 ells with maintained IFN-gamma production in skin test infiltrating lymphocyte (SKIL) cultures and ci

108 For most drugs, sensitivity of skin testing is higher in immediate hypersensitivity com

109 y of a stepwise approach to diagnosis, using skin tests, laboratory tests, and oral challenges.

110 ates were lower compared with the tuberculin skin test, likely reflecting the higher specificity of t

111 soluble Leishmania antigen and a Leishmania skin test (LST) were performed in years 0, 2, and 4.

112 0.0001) or home introduction after negative skin test (median 4.3, P < 0.0001).

113 owing that the performance of the tuberculin skin test might be affected by various factors including

114 Allergy skin tests must be carried out sequentially at the recom

115 r tuberculosis infection with the tuberculin skin test (n = 1389) and QuantiFERON assay (n = 576) and

116 l tests (n = 4), a syndromic reaction during skin tests (n = 1), and one case with grade 1 reaction a

117 subset of patients with positive penicillin skin tests (n = 295), only 1 had a hypersensitivity reac

118 lprit PPI that displayed negative results in skin tests (n = 61) and diagnostic OPTs with the suspect

119 ren had IFN-gamma release assay positive and skin test negative discordance.

120 phenotypes: skin test and lesion positive vs skin test negative on multiple occasions, respectively.

121 ith history-appropriate PCN skin testing: if skin test negative, give cefazolin (ST-Cefaz).

122 developed, including reaction to tuberculin skin test of the contacts, as well as smear-positivity,

123 to those in biopsy specimens from Montenegro skin tests of individuals with asymptomatic infection.

124 fect of using an alternative GBCA or allergy skin testing on the risk of a breakthrough reaction.

125 rate (81.06%; kappa coefficient 0.485), with skin-test-only positive results associated with the pres

126 d 17 years with either a positive tuberculin skin test or an immunocompromising condition, or contact

127 two chemically unrelated drugs, confirmed by skin test or in vitro assay.

128 to patients who were positive on tuberculin skin test or interferon gamma release assay (adjusted HR

129 een evaluated.Methods People with a positive skin test or interferon gamma release assay (IGRA) resul

130 h incidence areas irrespective of tuberculin skin test or interferon gamma release assay status.

131 l studies that applied either the tuberculin skin test or the interferon gamma release assay for diag

132 ctively measured atopy (measured by allergen skin tests or specific IgE).

133 volunteers reacted to rAed a 3 in either the skin tests or the IgE assays, confirming the specificity

134 edications or with long-lasting symptoms, on skin tests or the presence of serum-specific IgE antibod

135 P < .001), and baseline positive tuberculin skin test (OR, 2.21; P = .03); BCG vaccination was parti

136 " "prick or epicutaneous," and "intradermal" skin testing, "oral challenge or provocation," "cross-re

137 assays correlate better than the tuberculin skin test (P = 0.0011).

138 immunity (measured using phytohaemagglutinin skin test, p < 0.0001), thyroxine (T4, p = 0.042), and g

139 However, skin test performance is related to the quality of aller

140 cted using the ISAAC questionnaire, allergen skin tests performed, and stool samples analysed for H.

141 ernative regimen in HIV-positive, tuberculin skin test positive individuals.

142 In Group A, 72% were skin test positive; 28% required DPT.

143 In Group B, 63% were skin test positive; 37% required DPT.

144 Calmette-Guerin (BCG) in healthy, tuberculin skin test-positive (>/=15-mm induration), HIV-negative S

145 bsets from tuberculosis cases and tuberculin skin test-positive (TST(+)) and TST-negative (TST(-)) ho

146 Of 1406 skin test-positive contacts, TB developed in 49 (9.8%) o

147 peripheral blood of asymptomatic tuberculin skin test-positive individuals with recent (household) o

148 e recognized by immune cells from tuberculin skin test-positive, ESAT6/CFP10-responsive individuals,

149 ard IVE-TB Ags, albeit lower than tuberculin skin test-positive, ESAT6/CFP10-responsive individuals.

150 ks later by a late-winter peak in tuberculin skin test positivity and 12 weeks after that by an early

151 U/ml, and greater than 0.7 IU/ml, tuberculin skin test positivity results were 15%, 53%, 66%, and 91%

152 olymorphisms of HLA-DRA and ZNF300 predicted skin test positivity to amoxicillin and other penicillin

153 e-standardised and sex-standardised rates of skin-test positivity (>/=10 mm) ranged from 15% to 42%,

154 d animals, based primarily on the tuberculin skin test (PPD).

155 ntigens, the composition of past and current skin test preparations with particular attention to diff

156 The negative predictive value of the skin test protocol was calculated, defined as the ratio

157 Our skin test protocol with four simultaneously injected con

158 Penicillin skin testing (PST) with or without oral amoxicillin chal

159 d across the United States with a tuberculin skin test, QuantiFERON (R) Gold In-Tube test, and T-SPOT

160 Immediate skin test reactions to rAed a 3 correlated significantly

161 of latent tuberculosis infection (tuberculin skin test reactivity >/=10 mm), human immunodeficiency v

162 times can be confusing as patients with high skin test reactivity and high specific IgE (sIgE) levels

163 ent systemic reactions was higher in case of skin test reactivity to Apis mellifera or Vespula specie

164 kin 2 levels, and negatively with Leishmania skin test reactivity.

165 ho have had anaphylaxis, positive penicillin skin testing, recurrent penicillin reactions, or hyperse

166 (phenotype 1); ii) positive reactors to the skin test regardless of post-mortem examination results

167 se by IFN-gamma release assay and tuberculin skin test, 'resisting' development of classic LTBI".

168 se by IFN-gamma release assay and tuberculin skin test, 'resisting' development of classic LTBI.

169 ve by IFN-gamma release assay and tuberculin skin test, 'resisting' development of classic LTBI." The

170 based on the severity of the initial HSR and skin test response.

171 top doses of QGE031 consistently suppressed skin test responses among subjects but had a variable ef

172 e patients were more likely to have negative skin test responses and to have experienced a delayed or

173 nicity had a greater probability of positive skin test responses compared with Mexican asthmatic pati

174 3 times (95% CI, 1.62-5.57) as many positive skin test responses in asthmatic participants and 3.26 t

175 times (95% CI, 1.02-10.39) as many positive skin test responses in control participants.

176 ially in patients with negative or equivocal skin test responses inconsistent with the clinical prese

177 rty (18.7%) of the 214 subjects had positive skin test responses to at least 1 aminocephalosporin.

178 d positive patch test and/or delayed-reading skin test responses to at least 1 penicillin reagent.

179 Aeroallergen skin test responses were analyzed in 1830 US Latino subj

180 (sIgE) of 0.35 kU/L or greater had negative skin test responses, and these children also expressed t

181 ephalosporins and have negative pretreatment skin test responses.

182 rminant variable with the number of positive skin test responses.

183 action to lansoprazole had a positive OPT or skin test result with at least one of the alternative PP

184 Smaller skin test results and lower allergen-specific IgE levels

185 Significant within-group changes in skin test results and peanut-specific IgE and IgG4 level

186 All subjects displayed negative skin test results to both aztreonam and carbapenems; 211

187 All subjects had negative skin test results to cefuroxime, ceftriaxone, and aztreo

188 ate reactions to cephalosporins and positive skin test results to the responsible drugs underwent ser

189 HBV allergy (n = 144) was based on history, skin test results, and allergen-specific IgE levels to H

190 time of challenge, such subjects had smaller skin test results, as well as lower IgE levels specific

191 ifferences in age, milk-specific IgE levels, skin test results, or OFC results.

192 Prick-prick skin testing revealed positive responses to Stona IB Gel

193 desensitization candidates after anamnesis, skin testing, risk assessment, and graded challenge.

194 Considering the high specificity, skin testing seems to be a useful method for the diagnos

195 Full allergy evaluation with skin testing seems to be preferred, although more data a

196 There are studies demonstrating that skin-test sensitivity to penicillins can decrease over t

197 The secondary included skin test, serum specific IgE and IgG4, nasal allergen p

198 LQ), nasal allergen provocation test (NAPT), skin testing, serum levels of specific IgG4 and specific

199 Interpretation of skin testing should be made with caution.

200 At 3 months, skin test size and IgE to peanut Arah1 decreased to 4 mm

201 addresses availability and concentrations of skin test (ST) reagents, ST and drug provocation test (D

202 addresses availability and concentrations of skin test (ST) reagents, ST and drug provocation test (D

203 We analyzed the diagnostic value of a skin test (ST), drug provocation test (DPT) and basophil

204 posed individuals with a negative atracurium skin test (ST), two individuals had a clear positive BAT

205 um antitoxin and (2) the predictive value of skin testing (ST) before botulinum antitoxin administrat

206 : (1) standard of care (SOC), (2) penicillin skin testing (ST), and (3) computerized guideline applic

207 tam (BL) allergy workup, in case of negative skin tests (ST) and in the absence of contraindications.

208 457 (25.7%) were at first evaluation [403 by skin tests (ST), 12 by positive IgE and 42 by controlled

209 d diagnostic protocol by means of anamnesis, skin tests (ST), risk assessment, and DPT.

210 Skin tests (STs) and single-blind placebo-controlled dru

211 rology and, in prevaccination assessment, on skin tests (STs), which both have drawbacks.

212 1-2.9) and in a per-protocol analysis of the skin tested subset (aOR, 5.7; 95% CI, 2.6-12.5).

213 While the skin tested subset showed an almost 6-fold impact, the c

214 We conducted a tuberculin skin-test survey in 5,119 preschool children in the gene

215 tes derived from population-level tuberculin skin-test surveys using traditional cutoff methods.

216 ntation rate, C-reactive protein, tuberculin skin test, syphilis serology, and chest radiograph) foll

217 diagnostically compatible with a novel DIVA skin test that could be implemented in control programme

218 A skin test that detects dermal hypersensitivity in person

219 Surveillance for bTB is based on a skin test that measures an immunological response to tub

220 The tuberculin skin test, the traditional assay for diagnosing LTBI, ha

221 Peanut skin test titration and basophil activation (at a single

222 generated from seven patients with positive skin test to either AX or Clav.

223 onth post-transplant, the patient had a 6 mm skin test to peanut and had serum IgE to peanut Arah1 of

224 pigs in the control chamber converting their skin test to positive was 4.9 (95% confidence interval,

225 nt spirometry, exhaled nitric oxide, allergy skin testing to 10 common household allergens and provid

226 um antitoxin treatment and the usefulness of skin testing to assess this risk.

227 hing to an alternative GBCA or using allergy skin testing to decrease reaction risk lacked enough ava

228 Contacts underwent tuberculin skin testing to determine tuberculosis infection status.

229 The use of penicillin skin testing to evaluate for true allergies has been str

230 based on the severity of the initial HSR and skin testing to guide taxane reintroduction is safe and

231 Skin testing to mouse and other allergens and collection

232 Sensitization on skin testing to peanut (SPT response of 1-4 mm vs 0 mm)

233 challenge with or without proceeding formal skin testing to tackle penicillin allergy efficiently wi

234 splayed increased levels of IgE and positive skin tests to allergens with homologs in the parasite.

235 tions to penicillins and positive results on skin tests to at least 1 penicillin reagent underwent sk

236 All subjects displayed negative skin tests to carbapenems and tolerated challenges.

237 All tested patients showed positive skin tests to Erbitux((R)).

238 ma release assays (IGRAs) and the tuberculin skin test (TST) among PLWH are lacking.

239 nd at delivery for LTBI using the tuberculin skin test (TST) and IFN-gamma release assay (IGRA) (Quan

240 (QGIT) antepartum and by QGIT and tuberculin skin test (TST) at delivery and postpartum.

241 143627 (IL1B) as risk factors for tuberculin skin test (TST) conversion or development of active TB i

242 sehold member with TB or a recent tuberculin skin test (TST) conversion were included in this study.

243 The tuberculin skin test (TST) has a poor sensitivity in this setting.

244 RON-TB Gold In-Tube (QFT-GIT) and tuberculin skin test (TST) has not been compared in a US college po

245 ube (QFT-GIT), T-SPOT.TB, and the tuberculin skin test (TST) might improve prediction of incident TB.

246 viduals aged 12-50 years who were tuberculin skin test (TST) negative and eligible for BCG vaccinatio

247 same family sample, that controls tuberculin skin test (TST) negativity per se, that is, T-cell-indep

248 nd adults with LTBI have positive tuberculin skin test (TST) or interferon gamma release assay (IGRA)

249 tuberculosis case display lack of tuberculin skin test (TST) reactivity.

250 ousehold contacts with a positive tuberculin skin test (TST) result.

251 h programs that switched from the tuberculin skin test (TST) to IFN-gamma release assays for latent t

252 py, Xpert MTB/RIF (Cepheid Inc.), tuberculin skin test (TST), and chest radiography.

253 atent tuberculosis infection: the tuberculin skin test (TST), QuantiFERON-TB Gold (QFT-G), and T-SPOT

254 ially approved tests, namely, the tuberculin skin test (TST), the Quantiferon-TB Gold in-tube (QFT-GI

255 ulmonary tuberculosis (cases), 47 tuberculin skin test (TST)-positive controls, and 39 TST-negative c

256 fer improved specificity over the tuberculin skin test (TST).

257 GIT), T-SPOT.TB (T-SPOT), and the tuberculin skin test (TST).

258 st; 2) enroll based on a positive tuberculin skin test (TST); 3) enroll based on a positive IFN-gamma

259 secutive periods: first, a 2-step tuberculin skin test (TST); second, a 2-step TST plus QuantiFERON-T

260 ir Mtb infection status using the tuberculin skin test (TST; cohort 1) or QuantiFERON (QFT; cohort 2)

261 their Mtb infection status using Tuberculin skin test (TST; cohort 1) or QuantiFERON (QFT; cohort 2.

262 ssays (IGRAs) are alternatives to tuberculin skin testing (TST) for diagnosis of latent tuberculosis

263 ed screening as a replacement for tuberculin skin testing (TST) to simplify contact evaluation and im

264 entified by persistently negative tuberculin skin tests (TST) and interferon-gamma release assays (IG

265 using a TB risk assessment tool, tuberculin skin tests (TST) placed and read, TST results, and patie

266 gies, TB infection (TBI) testing (tuberculin skin test [TST] and interferon gamma release assay [IGRA

267 s controlling the response to the tuberculin skin test (TST1 and TST2) and the production of TNF-alph

268 Tuberculin skin tests (TSTs) and QFTs were performed at baseline an

269 nfected patients who had positive tuberculin skin tests (TSTs) were followed until tuberculosis diagn

270 rests upon a thorough history completed with skin testing using native extracts from crushed buds and

271 The drugs, doses and protocols for skin testing varied considerably.

272 A complementary diagnostic skin test was developed with the antigenic proteins enco

273 option of introducing at home without prior skin testing was associated with high levels of anxiety

274 Skin testing was undertaken by 87% of respondents who pe

275 Overall agreement among S1 and S2 skin tests was 70.45%.

276 between laboratory results and anamnesis and skin tests was achieved in many cases.

277 iven the long-winded procedure of sequential skin testing, we retrospectively explored the safety of

278 witching to an alternative GBCA, and allergy skin testing were assessed.

279 Inhaled allergen challenges and skin tests were conducted before dosing and at weeks 6,

280 Positive skin tests were obtained in 25/44 patients (57%).

281 Skin tests were performed 1, 3 and 6 months following tr

282 Skin tests were performed in two stages: (i) Stage 1 (S1

283 tified by age (</=5 and >5 years) and peanut skin test wheal size (</=10 and >10 mm); 56 reached the

284 Subjects with peanut skin test wheals of less than 5 mm and peanut-specific I

285 Peanut skin test wheals, peanut-specific IgE levels, and basoph

286 autoreactivity (a positive autologous serum skin test), whereas 50% are negative regarding both.

287 interfere with the action of the tuberculin skin test, which is used to determine if animals, herds

288 sk patients can be evaluated with penicillin skin testing, which carries a negative predictive value

289 ndicator traits: i) positive reactors to the skin test with positive post-mortem examination results

290 Negative delayed-reading skin testing with carbapenems in individuals with docume

291 Skin testing with penicillins was performed in duplicate

292 vity.To promote and standardize reproducible skin testing with safe and nonirritant drug concentratio

293 s to at least 1 penicillin reagent underwent skin tests with aztreonam and carbapenems; subjects with

294 rnative beta-lactams, all subjects underwent skin tests with cephalexin, cefaclor, cefadroxil, cefuro

295 serum specific IgE assays with cefaclor and skin tests with different cephalosporins.

296 All 204 subjects underwent skin tests with imipenem/cilastatin and meropenem; 130 o

297 Diagnosis was performed using skin tests with major and minor determinants of PG (PPL/

298 on-reactors and inconclusive reactors to the skin tests with positive post-mortem examination results

299 gative and positive predictive values of the skin tests with PPIs were 58.8%, 100%, 70.8%, and 100%,

300 All subjects with a positive tuberculin skin test without prior active tuberculosis were offered